The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens Wearers

NCT04297618 | Completed Phase 4 Results FDA Drug

• 1 other identifier: 41189
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study to evaluate changes in comfort and dryness in symptomatic contact lens (CL) wearers after using Xiidra (lifitegrast 5.0% ophthalmic solution) for 12 weeks.

Conditions

Dry Eye

Outcome Measures

Primary Outcomes (2)

• Difference in Contact Lens-related Discomfort at 12 Weeks Compared to Baseline

  Participants rate their contact lens-related discomfort on a scale from 0 (no discomfort) to 100 (maximal discomfort).

  Baseline and 12 weeks

• Difference in Contact Lens-related Dryness at 12 Weeks Compared to Baseline

  Participants rate their contact lens-related dryness on a scale from 0 (no discomfort) to 100 (maximal discomfort).

  Baseline and 12 weeks

Study Arms (1)

Xiidra treatment

EXPERIMENTAL

Each participant will use the same study drops, Xiidra, over the course of the 12-week study.

Drug: Xiidra

Interventions

Xiidra DRUG

Xiidra (lifitegrast 5% ophthalmic solution)

Also known as: Lifitegrast

Xiidra treatment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Is at least 18 years of age and has full legal capacity to volunteer;
• Has read and signed an information consent letter;
• Is willing and able to follow instructions and maintain the appointment schedule;
• Currently wears daily, soft, frequent replacement lenses (daily, bi-weekly or monthly disposable lenses) in both eyes, that are available in Canada, for a minimum of 5 days/week for 6 hours/day over the last month, and is willing to continue to do so during the study;
• Is a symptomatic CL wearer as determined by Eye Dryness Score4,5 (EDS) ≥40 at the end of the wear day AND according to the classification by Young et al7;
• Can achieve acceptable lens fit as well as visual acuity (VA) correctable to logMAR +0.20 or better in each eye with their habitual contact lens type;
• Has a history of artificial tear or rewetting drop use at least once in the last 30 days;
• Is willing to use the Xiidra study drops twice a day on a daily basis (irrespective of CL wear) and to stop use of any habitual rewetting drops and/or artificial tears over the course of the 12-week treatment phase;

You may not qualify if:

• Is participating in any concurrent clinical or research study;
• Is wearing soft CLs on an extended wear basis (i.e. overnight) or is a rigid gas permeable lens or hybrid lens wearer;
• Has a known sensitivity to the investigational product or diagnostic substances (e.g. fluorescein) to be used in the study;
• Has any known ocular disease and/or infection, that's either currently active\* or has occurred within the previous 30 days;
• Has a systemic condition that in the opinion of the investigator may affect a study outcome variable (examples may include active or uncontrolled systemic conditions such as allergies, autoimmune disease or immunodeficiency disease);
• Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable, including but not limited to topical cyclosporine, any other topical ophthalmic medication, antihistamines, and aspirin;
• Is pregnant, lactating or planning a pregnancy at the time of enrolment (by self-report);\*\*
• Has undergone refractive error surgery such as LASIK within the last 12 months;
• Has a history of yttrium-aluminium-garnet laser posterior capsulotomy within the previous 6 months,
• Is an employee of the Centre for Ocular Research \& Education; \* For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.

Sponsors & Collaborators

• University of Waterloo: lead
• Novartis: collaborator

Study Sites (1)

Centre for Ocular Research & Education

Waterloo, Ontario, N2L 3G1, Canada

Location

MeSH Terms

Conditions

Dry Eye Syndromes

Interventions

lifitegrast

Condition Hierarchy (Ancestors)

Lacrimal Apparatus Diseases; Eye Diseases

Results Point of Contact

• Title: Jill Woods
• Organization: Centre for Ocular Research and Education

jwoods@uwaterloo.ca

(519) 888-4567

Study Officials

• Lyndon Jones, PhD, FCOptom

  Centre for Ocular Research & Education

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 3, 2020
• First Posted: March 5, 2020
• Study Start: July 7, 2021
• Primary Completion: April 18, 2024
• Study Completion: April 18, 2024
• Last Updated: May 4, 2025
• Results First Posted: May 4, 2025

Record last verified: 2024-06

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)